Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd. announced that it will receive CNY 105 million in an equity round of funding from returning investor ShanXi C&Y Pharmaceutical Group Co., Ltd. on June 2, 2022. The investor will retain 100% stake in the company. After the completion of this capital increase, the registered capital of will increase from CNY 255,000,000 yuan to CNY 36,000,000.

The transaction has been approved at the 4th board of directors and the 17th meeting of the 4th board of supervisors and does not need to be submitted to the company's general meeting of shareholders for consideration.